<DOC>
	<DOCNO>NCT00399685</DOCNO>
	<brief_summary>The purpose study administer combine oral contraceptive contain ethinyl estradiol norgestimate HIV treatment efavirenz healthy female order ass concentration oral contraceptive change . The safety treatment regimen also study .</brief_summary>
	<brief_title>Drug Interaction - Oral Contraceptive</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Women childbearing potential intact ovarian function stable method oral contraceptive least 2 month prior start study . Documented acceptable Pap smear within 1 year start study BMI 1832 kg/mÂ² Males Subjects abnormal menstrual cycle within 2 month prior start study History condition oral contraceptive contraindicate History migraine focal aura History uncontrolled hypertension Positive screen test HIV1,2 , HIV viral RNA , Hepatitis B surface antigen , Hepatitis C antibody History diagnose mental illness suicidal ideation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV</keyword>
</DOC>